AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice.

Anni Kujala,Elina Valkonen,Hanna Sallinen,Laura Tuppurainen,Hanne Laakso,Elias Ylä-Herttuala,Timo Liimatainen,Jouni Kujala,Otto Jokelainen,Reijo Sironen,Maarit Anttila,Seppo Ylä-Herttuala

Frontiers in medicine（2022）

引用 0|浏览4

暂无评分

摘要

Combined use of the AAV8-sVEGFR2 and AAV8-sVEGFR3 with chemotherapy reduces intratumoral angiogenesis and tumor growth in OVCA mouse model. Results provide preclinical proof-of-concept for the use of soluble decoy VEGFRs and especially the AAV8-sVEGFR2 in the treatment of OVCA.

查看译文

关键词

MRI,angiogenesis,antiangiogenic,lymphangiogenesis,ovarian cancer,xenograft

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要